Search
SIGA Technologies Inc
SIGAAdd to Watchlist
3.860USD
+0.140+3.76%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
276.86MMarket Cap
13.64P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.76%
5 Days
-1.53%
1 Month
-12.87%
6 Months
-38.44%
Year to Date
-36.82%
1 Year
-42.30%
Key Figures
3.750Open
3.945High
545.66KVolume
13.64P/E TTM
3.67P/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
3.720Prev. Close
3.750Low
1.36MTurnover
4.68P/E Static
1.83P/B
0.00%Div Yield TTM
8.68%ROA
8.51052wk High
0.82Volume Ratio
59.21MNet Profit
71.72MShares
0.2830EPS TTM
0.92Beta
11.00%ROE
4.09552wk Low
5.24%Amplitude
52.89%Gross Margin
276.86MMarket Cap
-6.04Reward/Risk
2.65%Risk Rate
TradingKey Stock Score of SIGA Technologies Inc
Currency: USD Updated: 2026-07-02Key Insights
SIGA Technologies Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
SIGA Technologies Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
SIGA Technologies Inc Highlights
StrengthsRisks
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Growing
The company is in a growing phase, with the latest annual income totaling USD 94.57M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 72.80%.
Overvalued
The company’s latest PE is 13.64, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.67M shares, increasing 0.80% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 689.22 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
SIGA Technologies Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
SIGA Technologies Inc Info
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Ticker SymbolSIGA
CompanySIGA Technologies Inc
CEONguyen (Diem)
Websitehttps://www.siga.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of SIGA Technologies Inc (SIGA)?
The current price of SIGA Technologies Inc (SIGA) is 3.86.
What is the symbol of SIGA Technologies Inc?
The ticker symbol of SIGA Technologies Inc is SIGA.
What is the 52-week high of SIGA Technologies Inc?
The 52-week high of SIGA Technologies Inc is 8.51.
What is the 52-week low of SIGA Technologies Inc?
The 52-week low of SIGA Technologies Inc is 4.09.
What is the market capitalization of SIGA Technologies Inc?
The market capitalization of SIGA Technologies Inc is 276.86M.
What is the Earnings Per Share (EPS TTM) of SIGA Technologies Inc (SIGA)?
The Earnings Per Share (EPS TTM) of SIGA Technologies Inc (SIGA) is 0.33.